(Update 2) Experts Debate Link Between Vytorin, Cancer

Boston (dbTechno) - Medical experts continue the debate over the possible link between the FDA approved cholesterol-lowering drug Vytorin, and the risk of developing cancer.

The FDA approved Vytorin, from Merck & Co. and Schering-Plough Corp. some time ago.

It was approved after it was proven to be very effective in helping by lowering bad cholesterol in the blood of patients, and by promoting the increase of good cholesterol.

Vytorin is a very popular drug, with the sales of it amounting into billions of dollars each and every year.

More recently though, it has turned into the center of a great deal of controversy.

Medical experts are trying to figure out whether or not the cholesterol-lowering drug actually increases the risk of developing cancer.

The drug, though helpful in the cholesterol field, was never proven to prevent heart attacks, or any other cardiovascular disease.

On top of that, many medical experts believe it may be linked to cancer.

The latest research has been released in the New England Journal of Medicine in the form of an editorial pice.

The editorial piece focused on studies which were carried out on the drug Vytorin.

The editorial stated basically that there was no way as of right now to actually prove whether or not the drug increased the risk of cancer.

At the same time though, the data provided in the study has been unable to actually say that cancer was not linked to Vytorin either.

This information will be used to further the debate, which was presented at the European Society of Cardiology conference this week.